The concern of generic competition has long loomed over copyright’s iconic drug, Viagra, sparking questions about the outlook of related medicinal portfolios. While early periods saw significant gains, the exclusivity end has created the door for cheaper copies, likely reducing revenue and creating a significant risk for stakeholders looking for